RESEARCH ARTICLE


Efalizumab in Psoriasis: Our Experience with 11 Patients



C. Rodriguez-Cerdeira*, 1, S. Diez-Moreno1, A. Molares1, A. Guerra-Tapia2
1 Department of Dermatology, Complejo Hospitalario de Vigo and Vigo University, Vigo, Spain
2 Department of Dermatology, Hospital 12 Octubre, Madrid, Spain


Article Metrics

CrossRef Citations:
1
Total Statistics:

Full-Text HTML Views: 438
Abstract HTML Views: 1422
PDF Downloads: 672
Total Views/Downloads: 2532
Unique Statistics:

Full-Text HTML Views: 296
Abstract HTML Views: 878
PDF Downloads: 462
Total Views/Downloads: 1636



Creative Commons License
© 2010 Rodriguez-Cerdeira et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Dermatology, CHUVI, Meixoeiro Hospital & University of Vigo, 36200 Vigo, Spain; Tel: 0034600536114; Fax: 0034986276416; E-mails: Carmen.Rodriguez.Cerdeira@sergas.es, aristoteles_cerdeira@yahoo.es


Abstract

This is an observational, longitudinal and retrospective study of a group of patients with moderate to severe plaque psoriasis whom had been treated with efaluzimab (1mg/Kg/week) for up to 20 weeks. Nevertheless, first dose of 0.7 mg/kg was given. The efficacy of the drug was evaluated by measuring the psoriasis area and severity index (PASI), the body surface area (BSA) and index of the quality of life (DLQI).

A statically significant improvement was observed in the PASI, BSA and DLQI after 4, 12 and 20 weeks of therapy.

After 20 weeks of treatment, the PASI 75 and 90 values were 100% and 97% respectively. When it comes to safety, efaluzimab was well tolerated and no remarkable side effects were recorded.

Keywords: Efaluzimab, psoriasis, treatment, safety.